Ascletis Pharma

Executive Summary

Ascletis Pharma is a commercial-stage biopharmaceutical company based in Hangzhou, China, focused on infectious diseases, oncology, and metabolic disorders. The company has established a commercial presence with its all-oral, direct-acting antiviral regimen for hepatitis C (HCV), which is marketed in China. Leveraging a balanced strategy of in-licensing and internal R&D, Ascletis has built a diverse pipeline of small molecules and biologics targeting high unmet medical needs. Its lead oncology candidate, ASC40 (a FASN inhibitor), is in Phase II for non-alcoholic steatohepatitis (NASH) and Phase I for glioblastoma, while ASC09 (an HIV protease inhibitor) and ASC18 (a fixed-dose combination for HCV) represent key infectious disease programs. The company also explores metabolic indications such as NASH and obesity through ASC41 and ASC43. Looking ahead, Ascletis is positioned to unlock value from multiple catalysts. The near-term focus is on advancing ASC40 into pivotal trials for NASH, a large global market, and reporting Phase II data for its oncology pipeline. Additionally, regulatory progress in China, including potential label expansions for its HCV franchise, could drive revenue growth. Despite competitive pressure in HCV and early-stage pipeline risks, Ascletis's commercial infrastructure and China-focused strategy provide a foundation for sustainable growth. The company's deep pipeline and partnerships (e.g., with Shenox) offer multiple shots on goal, but near-term catalysts are tempered by the early stage of most pipeline assets.

Upcoming Catalysts (preview)

• H2 2026ASC40 NASH Phase II topline data45% success
• Q3 2026ASC40 GBM Phase I/II interim efficacy update30% success
• Q4 2026China NMPA approval for HCV label expansion (GT3/6)80% success